Send to:

Choose Destination
See comment in PubMed Commons below
Am J Hematol. 2008 Sep;83(9):744-6. doi: 10.1002/ajh.21231.

CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.

Author information

  • 1Department of Medicine, State University of New York, Upstate Medical University, Syracuse, New York 13210, USA.


CD8+ cutaneous T-cell lymphoma (CTCL) is a relatively rare subset of the non-Hodgkins lymphomas. Bexarotene has been FDA-approved for the treatment of CTCL, but previous studies have been conducted on CD4+ CTL and there have been no reports about its use in CD8+ CTCL. Herein, we report on a patient whose CD8+ CTCL completely responded to treatment with bexarotene.

Copyright 2008 Wiley-Liss, Inc.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc.
    Loading ...
    Write to the Help Desk